Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956906 | 0.84 | LMNA (0.51) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL2958606 | 0.83 | POLB (0.46) | ALDH1A1HPGDKDM4EPOLBGAA | |
| SCHEMBL2964860 | 0.79 | ALDH1A1 (0.52) | ALDH1A1HPGDHSD17B10POLBMAPK1 | |
| SCHEMBL2958198 | 0.76 | MAPT (0.50) | ALDH1A1HPGDHSD17B10KDM4EPOLB | |
| SCHEMBL11425177 | 0.74 | TTR (0.51) | ALDH1A1HPGDHSD17B10KDM4ETTR | |
| SCHEMBL8470768 | 0.74 | CYP1A2 (0.60) | ALDH1A1HPGDKDM4ECYP1A2KMT2A | |
| SCHEMBL2957087 | 0.74 | AHR (0.56) | ALDH1A1HPGDHSD17B10KDM4ETTR | |
| Methane SCHEMBL10547214 | 0.73 | TTR (0.50) | ALDH1A1HPGDHSD17B10KDM4ETTR | |
| SCHEMBL2965345 | 0.73 | CYP1A2 (0.51) | ALDH1A1HPGDHSD17B10KDM4ETTR | |
| SCHEMBL11270958 | 0.72 | HTT (0.51) | KDM4EPOLBGAAHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772237-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2009-04-23 | — | — | US | disclosed |
| US-7476690-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2009-01-13 | — | — | US | disclosed |
| EP-1735300-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7119214-B2 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-12-22 | — | — | US | disclosed |
| WO-2005100345-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | CEPHALON FRANCE (FR) | 2005-10-27 | — | — | WO | disclosed |
| EP-1589016-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | CEPHALON FRANCE (FR) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282821-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885HPGD 3681/4885HSD17B10 1734/4885 |
| US-20060241119-A1 | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885HPGD 3681/4885HSD17B10 1734/4885 |
| US-20090105241-A1 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES | HTR1A, HTR2A, HTR5A | ALDH1A1 2457/4885HPGD 3681/4885HSD17B10 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.